Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Date:11/5/2008

CALGARY, Nov. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Thursday, November 6, 2008 at 11:00 a.m. MT (1:00 p.m. ET) to update investors on clinical trial results in its U.S. Phase II trial for patients with bone and soft tissue sarcomas metastatic to the lung. The results are scheduled to be presented November 6, 2008 at the Chemotherapy Foundation Symposium XXVI in New York.

To access the conference call by telephone, dial 1-416-915-5651 or 1-800-732-6179. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2471700, or through the Company's website at http://www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at http://www.oncolyticsbiotech.com and will also be available by telephone through November 13, 2008. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 21288636 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release c
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ST. LOUIS , June 2, 2015 /PRNewswire/ ... leading Life Science and Technology company, announced today ... XCell Science to launch genetically engineered human ... to advance the research of neurological diseases. These ... portfolio, provide unique and versatile tools for the ...
(Date:6/2/2015)... 02, 2015 Through rare discovery of ... Yancy Corporation is enabling World Scientists to actually ... biological sample, displaying the full nature (position, shape, size, ... , Jeff Porter, Co-Founder of the Yancy Corporation, says, ... – rare. They come once in a lifetime, if ...
(Date:6/1/2015)... YORK , June 1, 2015  Turing ... researcher  Eliseo Oreste Salinas , MD, MSc,  has ... development. Dr. Salinas, who holds a ... pharmacology, brings a record of significant accomplishments in ... psychiatry.  Dr. Salinas has played a ...
(Date:6/1/2015)... YORK , June 1, 2015 ... by the fermentation of sugar or cellulose. Bio-alcohols are ... can be used as a replacement for gasoline in ... grow at a CAGR of 9 percent over the ... The global bio-alcohols market can be segmented into five: ...
Breaking Biology Technology:Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Global Bio-alcohols Market 2015-2019 2
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
... 2010 Kendle (Nasdaq: KNDL ), a ... business awards for the third quarter of 2010 of ... quarter moderated significantly to $10.4 million or 1.3 percent ... in a net book-to-bill of 1.5. New business authorizations ...
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
Cached Biology Technology:Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company ... to present at the 24th Annual Oppenheimer Healthcare Conference, which ... December 10-11, 2013. Organovo,s Chairman and Chief ... Wednesday, December 11, at 2:45pm ET. The objective ...
... soak up a dangerous pore-forming toxin produced by MRSA ... safe and effective vaccine against this toxin. This "nanosponge ... the adverse effects of the alpha-haemolysin toxin from MRSAboth ... the University of California, San Diego described the safety ...
... proteins just beneath its surface until it is trapped as ... hits of energy eventually power the growth and movement of ... life. The three clumps of protein a light-harvesting ... look like random scrawls in illustrations but this is misleading. ...
Cached Biology News:Organovo to Present at the 24th Annual Oppenheimer Healthcare Conference 2'Nanosponge vaccine' fights MRSA toxins 2'Nanosponge vaccine' fights MRSA toxins 3'Nanosponge vaccine' fights MRSA toxins 4Scientists stitch up photosynthetic megacomplex 2Scientists stitch up photosynthetic megacomplex 3
Request Info...
Request Info...
Request Info...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Biology Products: